viewMotif Bio PLC

Motif Bio gets confirmation of requirements for new iclaprim trial

Motif has now received the minutes of its Type B meeting with the US Food and Drug Administration in September

Motif Bio PLC -

Motif Bio PLC (LON:MTFB) has received official confirmation of the parameters of a new trial to get US approval for its iclaprim antibiotic.

Minutes of a Type B meeting between Motif and US Food and Drug Administration in September indicated a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with bacterial pneumonia (HABP/VABP), along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application.

Motif Bio repeated that it would take several years to enrol and complete a HABP/VABP Phase III trial and cost tens of millions of dollars hence its decision to either find a partner to pay for the trial or else dispose of iclaprim to a firm with deeper pockets.

The FDA is concerned about possible liver toxicity with iclaprim, something that emerged following the submission of trial data from two phase III assessments of the drug.

Graham Lumsden, chief executive, said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval.

"The company is working hard to find a partner or other entity to complete the HABP/VABP Phase III trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."

Quick facts: Motif Bio PLC

Price: 0.751 GBX

Market: AIM
Market Cap: £4.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

1 day, 11 hours ago

2 min read